Fresenius   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Frankfurt Germany (1912)

Organization Overview

First Clinical Trial
2003
NCT00515736
First Marketed Drug
1948
lidocaine (xylocaine)
First NDA Approval
1948
epinephrine (levophed)
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

EUROHEAD | FRESENIUS | Fresenius AG | Fresenius Biotech North America | Fresenius Hemocare | Fresenius Kabi | FRESENIUS KABI | Fresenius Kabi Austria GmbH, Graz | Fresenius Kabi Japan | FRESENIUS KABI ONCOL | Fresenius Kabi Oncology Ltd. | Fresenius Kabi SwissBioSim GmbH | FRESENIUS KABI USA | Fresenius Kabi USA, LLC | FRESENIUS MEDCL | Fresenius Medical Care Deutschland GmbH | Fresenius Medical Care Korea | Fresenius Medical Care North America | Fresienius Kabi HK Ltd | Randolph Quinn | VIFOR FRESENIUS | Vifor Fresenius Medical Care Renal Pharma | Xenios AG